```
     FILE 'REGISTRY' ENTERED AT 16:09:37 ON 20 AUG 2007
L1              STRUCTURE UPLOADED
L2           50 S L1
L3              STRUCTURE UPLOADED
L4           50 S L3
L5       220203 S L3 SSS FULL

     FILE 'STNGUIDE' ENTERED AT 16:11:38 ON 20 AUG 2007

     FILE 'HCAPLUS' ENTERED AT 16:13:22 ON 20 AUG 2007
L6          8189 S L5/THU
L7         68084 S ALZHEIMER OR DONEPEZIL OR ACETYLCHOLINESTERASE

     FILE 'STNGUIDE' ENTERED AT 16:14:07 ON 20 AUG 2007

     FILE 'HCAPLUS' ENTERED AT 16:14:48 ON 20 AUG 2007
L8         20980 S (NMDA OR (N-METHYL-D-ASPARTATE))(W)(INHIB? OR ANTAGON? OR REC
L9            38 S L6 AND L7 AND L8
L10           13 S L9 AND (PY<2003 OR AY<2003 OR PRY<2003)

     FILE 'HCAPLUS' ENTERED AT 16:33:07 ON 20 AUG 2007
L11         1072 S NERAMEXANE OR MEMANTINE
L12        24047 S DONEPEZIL OR ACETYLCHOLINESTERASE

     FILE 'STNGUIDE' ENTERED AT 16:33:09 ON 20 AUG 2007

     FILE 'HCAPLUS' ENTERED AT 16:33:55 ON 20 AUG 2007
L13          279 S (L8 OR L11) AND L12

     FILE 'HCAPLUS' ENTERED AT 16:34:27 ON 20 AUG 2007
L14           90 S L13 AND (PY<2003 OR AY<2003 OR PRY<2003)

     FILE 'HCAPLUS' ENTERED AT 16:34:50 ON 20 AUG 2007
L15           31 S L11 AND L14

     FILE 'REGISTRY' ENTERED AT 16:48:44 ON 20 AUG 2007
                EXP NERAMEXANE/CN
L16            1 S E3

     FILE 'STNGUIDE' ENTERED AT 16:49:08 ON 20 AUG 2007

     FILE 'HCAPLUS' ENTERED AT 16:49:58 ON 20 AUG 2007
L17            7 S L12 AND L16
L18            2 S L17 AND (PY<2003 OR AY<2003 OR PRY<2003)
```

```
=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 16:09:37 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 AUG 2007  HIGHEST RN 944998-48-5
DICTIONARY FILE UPDATES:  19 AUG 2007  HIGHEST RN 944998-48-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10691895generic2.str
```





chain nodes :
7 8 10 11 13 14 15 16 17 18 20 21 22 27 28
ring nodes :
1 2 3 4 5 6
chain bonds :
1-16 1-17 2-18 2-20 3-21 3-22 4-7 4-13 5-10 5-11 6-14 6-15 7-8 8-27
8-28
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-16 1-17 2-18 2-20 3-21 3-22 4-13 5-10 5-11 6-14 6-15 7-8 8-27 8-28

exact bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6
isolated ring systems :
containing 1 :

```
G1:C,H

G2:Ak,H

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  10:CLASS  11:CLASS
13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS  20:CLASS  21:CLASS
22:CLASS  27:CLASS
28:CLASS



L1      STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 16:09:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    69034 TO ITERATE

  2.9% PROCESSED     2000 ITERATIONS                                  50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:      1365034 TO  1396326
PROJECTED ANSWERS:          373486 TO   390030

L2           50 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10691895specific4.str
```





chain nodes :
7 8 10 11 16 17 18 19 20 21 23 24 25 26 27
ring nodes :
1 2 3 4 5 6
chain bonds :
1-21 1-23 2-19 2-20 3-17 3-18 4-7 4-16 5-26 5-27 6-24 6-25 7-8 8-10
8-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-21 1-23 2-19 2-20 3-17 3-18 4-16 5-26 5-27 6-24 6-25 8-10 8-11
exact bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 7-8
isolated ring systems :
containing 1 :

G1:H,CH3,Et,n-Pr,i-Pr

Connectivity :
1:7 X maximum RC ring/chain 2:7 X maximum RC ring/chain 3:7 X maximum RC ring/chain
4:7 X maximum RC ring/chain 5:7 X maximum RC ring/chain 6:7 X maximum RC ring/chain
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 10:CLASS 11:CLASS
16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 23:CLASS 24:CLASS
25:CLASS 26:CLASS
27:CLASS

L3 STRUCTURE UPLOADED

=> s l3
SAMPLE SEARCH INITIATED 16:10:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 53979 TO ITERATE

  3.7% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 1065722 TO 1093438
PROJECTED ANSWERS: 227251 TO 240207

L4 50 SEA SSS SAM L3

=> d l3
L3 HAS NO ANSWERS
L3 STR



G1 H,Me,Et,n-Pr,i-Pr

Structure attributes must be viewed using STN Express query preparation.

=> s l3 sss full
FULL SEARCH INITIATED 16:11:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1081903 TO ITERATE

92.4% PROCESSED 1000000 ITERATIONS 220203 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.10

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1081903 TO 1081903
PROJECTED ANSWERS: 236776 TO 239700

L5 220203 SEA SSS FUL L3

=> d l5 scan

L5 220203 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3H-Imidazo[4,5-b]pyridine-7-carboxamide, 2-(4-fluorophenyl)-N-(3,3,5-trimethylcyclohexyl)-
MF C22 H25 F N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L5 220203 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C23 H32 N4 O3 S

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 220203 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C6 H14 N2 . H . 1/2 S4 W

CM 1



●2 H^+

CM 2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 220203 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Methanone, (4-cyclobutyl-1-piperazinyl)[trans-4-[[4-(trifluoromethyl)phenyl]amino]cyclohexyl]-
MF C22 H30 F3 N3 O

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 220203 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Methanone, [4-(1-methylethyl)-1-piperazinyl][trans-4-[[5-(methylsulfonyl)-2-pyridinyl]amino]cyclohexyl]-
MF C20 H32 N4 O3 S

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	173.00	173.21

FILE 'STNGUIDE' ENTERED AT 16:11:38 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 17, 2007 (20070817/UP).

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.18	173.39

FILE 'HCAPLUS' ENTERED AT 16:13:22 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 20 Aug 2007 VOL 147 ISS 9
FILE LAST UPDATED: 19 Aug 2007 (20070819/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l5/thu

         39560 L5
        925204 THU/RL
L6        8189 L5/THU
                (L5 (L) THU/RL)

=> s (NMDA or (N-methyl-d-aspartate))(w)(inhib? or antagon? or receptor))

UNMATCHED RIGHT PARENTHESIS 'RECEPTOR))'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s alzheimer or donepezil or acetylcholinesterase

         46292 ALZHEIMER
          1130 DONEPEZIL
         23372 ACETYLCHOLINESTERASE
L7       68084 ALZHEIMER OR DONEPEZIL OR ACETYLCHOLINESTERASE

=> s l6 and l7 and l8

L8 NOT FOUND
The L-number entered could not be found.  To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l9 and (PY<2003 or AY<2003 or PRY<2003)

L9 NOT FOUND
The L-number entered could not be found.  To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> file stnguide

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                  ENTRY     SESSION
FULL ESTIMATED COST                                2.60      175.99

FILE 'STNGUIDE' ENTERED AT 16:14:07 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 17, 2007 (20070817/UP).

=> file hcaplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                  ENTRY     SESSION
FULL ESTIMATED COST                                0.06      176.05

FILE 'HCAPLUS' ENTERED AT 16:14:48 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 20 Aug 2007 VOL 147 ISS 9
FILE LAST UPDATED: 19 Aug 2007 (20070819/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s (NMDA or (N-methyl-d-aspartate))(w)(inhib? or antagon? or receptor)

         28068 NMDA
       3071910 N
       1019329 METHYL
       2481312 D
         63102 ASPARTATE
         15192 N-METHYL-D-ASPARTATE
                 (N(W)METHYL(W)D(W)ASPARTATE)
       1956195 INHIB?
        301606 ANTAGON?
        713036 RECEPTOR
L8   20980 (NMDA OR (N-METHYL-D-ASPARTATE))(W)(INHIB? OR ANTAGON? OR RECEPT
               OR)

=> s l6 and l7 and l8

L9   38 L6 AND L7 AND L8

=> s l9 and (PY<2003 or AY<2003 or PRY<2003)

      22880660 PY<2003
       4450548 AY<2003
       3929122 PRY<2003
L10   13 L9 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> file stnguide

COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   2.60   178.65

FILE 'STNGUIDE' ENTERED AT 16:14:55 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 17, 2007 (20070817/UP).

=> d l10 1-13 ti
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L10 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI   Preparation of pyrazole derivatives and their use as protein kinase
     inhibitors

L10 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI   Tetracycline compounds having target therapeutic activities

L10 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI   Therapeutic formulations for the treatment of beta-amyloid related

diseases containing two active ingredients

L10 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Therapeutic formulations for the treatment of beta-amyloid related diseases containing 3 different types of agents

L10 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Compositions and methods using NMDA antagonists for treating neurological disease and providing neuroprotection

L10 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of protein Tau

L10 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds

L10 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Tetracycline compounds having target therapeutic activities

L10 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Thiazole derivatives and their use as cdk inhibitors, including combinations and pharmaceutical compositions

L10 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of carboxamides as NMDA receptor antagonists

L10 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI The N-methyl-d-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonize 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner

L10 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

L10 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of hydrogenated pyrido[4,3-b]indole derivatives and pharmaceutical compositions and a method for treating neurodegenerative diseases

=> d l10 1 3 4 5 6 8 10 11 12 ti abs bib hitstr
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L10 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of pyrazole derivatives and their use as protein kinase inhibitors
GI



I

AB Pyrazole derivs. [I; wherein R1 = straight chain or branched (C1-C1)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, (3-8 membered) heterocycloalkyl, (C5-C11)bicycloalkyl, (C7-C11)bicycloalkenyl, or (5-11 membered) heterobicycloalkyl; R2 = H, F, -CH3, -CN, or carboxy; R3 = amide, carboxy, etc.; R4 = straight chain or a branched (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8 alkynyl), (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, (3-8 membered) heterocycloalkyl, (C5-C11)bicycloalkyl, (C7-C11)bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (C6-C14)aryl, or (5-14 membered) heteroaryl] were prepared The prepared compds. are indicated to have activity inhibiting cdk2, cdk5, and GSK-3. Pharmaceutical compns. containing I can be used to treat or prevent diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those conditions that can be affected by inhibiting GSK-3.

AN 2005:1026614 HCAPLUS <<LOGINID::20070820>>

DN 143:326356

TI Preparation of pyrazole derivatives and their use as protein kinase inhibitors

IN Sanner, Mark A.; Helal, Christopher J.; Kung, Daniel W.

PA Pfizer Inc, USA

SO U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. Ser. No. 941,001.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005209297	A1	20050922	US 2005-132044	20050518 <--
	US 2002103185	A1	20020801	US 2001-941001	20010828 <--
PRAI	US 2000-229415P	P	20000831 <--		
	US 2000-232032P	P	20000912 <--		
	US 2001-941001	A2	20010828 <--		

OS MARPAT 143:326356

IT 865318-41-8P, N-[5-(cis-3-Acetylaminocyclobutyl)-2H-pyrazol-3-yl]-2-((cyclohexylmethyl)amino)acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrazole derivs. and use as protein kinase inhibitors for treating abnormal cell growth, neurodegenerative diseases, and other diseases)

RN 865318-41-8 HCAPLUS

CN Acetamide, N-[5-[cis-3-(acetylamino)cyclobutyl]-1H-pyrazol-3-yl]-2-[(cyclohexylmethyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L10 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Therapeutic formulations for the treatment of beta-amyloid related diseases containing two active ingredients
AB This invention relates to methods and pharmaceutical compns. for treating amyloid-β related diseases, including Alzheimer's disease. The invention, for example, includes a method of concomitant therapeutic treatment of a subject, comprising administering an effective amount of a first agent and a second agent, wherein said first agent treats an amyloid-β disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement. Pharmaceutical compns. containing compds. of the invention and a kit containing pharmaceutical formulations of the invention are also claimed.
AN 2004:565091 HCAPLUS <<LOGINID::20070820>>
DN 141:99726
TI Therapeutic formulations for the treatment of beta-amyloid related diseases containing two active ingredients
IN Gervais, Francine; Bellini, Francesco
PA Neurochem International Limited, Switz.
SO PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058258	A1	20040715	WO 2003-CA2011	20031224 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2511606	A1	20040715	CA 2003-2511606	20031224 <--
	AU 2003291910	A1	20040722	AU 2003-291910	20031224 <--
	EP 1585520	A1	20051019	EP 2003-767368	20031224 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003017747	A	20051122	BR 2003-17747	20031224 <--
	CN 1753662	A	20060329	CN 2003-80109946	20031224 <--
	CN 1753675	A	20060329	CN 2003-80109952	20031224 <--
	JP 2006512417	T	20060413	JP 2005-509679	20031224 <--
	US 2005031651	A1	20050210	US 2004-871537	20040618 <--
	NO 2005003077	A	20050922	NO 2005-3077	20050623 <--
	MX 2005PA06940	A	20060222	MX 2005-PA6940	20050624 <--
	IN 2005CN01675	A	20070622	IN 2005-CN1675	20050722 <--
PRAI	US 2002-436379P	P	20021224	<--	
	US 2003-482214P	P	20030623		
	US 2003-480906P	P	20030623		
	US 2003-480918P	P	20030623		
	US 2003-480984P	P	20030623		
	US 2003-482058P	P	20030623		
	US 2003-512017P	P	20031017		
	US 2003-512047P	P	20031017		
	US 2003-512116P	P	20031017		
	US 2003-512135P	P	20031017		
	US 2003-746138	A2	20031224		
	WO 2003-CA2011	W	20031224		

OS MARPAT 141:99726
IT 73463-39-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(therapeutic formulations containing two active ingredients for treatment of beta-amyloid related diseases and conditions associated with these diseases)

RN 73463-39-5 HCAPLUS

CN 1-Propanesulfonic acid, 3-(cyclohexylamino)-2-hydroxy- (CA INDEX NAME)



L10 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Therapeutic formulations for the treatment of beta-amyloid related diseases containing 3 different types of agents

AB The method is used for preventing or treating an amyloid-β related disease in a subject. The method comprises administering to a subject in need thereof an effective amount of a first agent that prevents or treats amyloid-β related disease, and a second agent that is (i) a peptide or peptidomimetic that modulates amyloid-β fibril formation or induces a prophylactic or therapeutic immune response against amyloid-β fibril formation, or (ii) an immune system modulator that prevents or inhibits amyloid-β fibril formulation. Therapeutic formulations containing compds. of the invention as well as kits containing the formulations are also claimed.

AN 2004:565074 HCAPLUS <<LOGINID::20070820>>

DN 141:99725

TI Therapeutic formulations for the treatment of beta-amyloid related diseases containing 3 different types of agents

IN Gervais, Francine; Bellini, Francesco

PA Neurochem International Limited, Switz.

SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058239	A1	20040715	WO 2003-CA2021	20031224 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2511599	A1	20040715	CA 2003-2511599	20031224 <--
	AU 2003292936	A1	20040722	AU 2003-292936	20031224 <--
	EP 1581203	A1	20051005	EP 2003-788737	20031224 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1753662	A	20060329	CN 2003-80109946	20031224 <--
	CN 1753675	A	20060329	CN 2003-80109952	20031224 <--
	JP 2006525226	T	20061109	JP 2005-509680	20031224 <--
	US 2006135403	A1	20060622	US 2005-540763	20051118 <--

PRAI US 2002-436379P P 20021224 <--
US 2003-482214P P 20030623
WO 2003-CA2021 W 20031224
OS MARPAT 141:99725
IT 73463-39-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic formulations for treatment of beta-amyloid related diseases containing 3 different types of agents)
RN 73463-39-5 HCAPLUS
CN 1-Propanesulfonic acid, 3-(cyclohexylamino)-2-hydroxy- (CA INDEX NAME)



L10 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Compositions and methods using NMDA antagonists for treating neurological disease and providing neuroprotection
AB The invention provides pharmaceutical compns. and methods of use thereof for the acute, chronic, and prophylactic treatment of neurol. and neurodegenerative diseases, attenuation of acute or chronic neuronal damage in neurol. disease (neuroprotection), and prophylaxis of neurol. diseases, where the neurol. diseases may involve excessive stimulation of the NMDA receptor, hypofunction of the NMDA receptor, up- or down regulation of the NMDA receptor, and abnormal subunit structure or function of the NMDA receptor. The pharmaceutical compns. are open-channel antagonists of the NMDA receptor complex, and include memantine, felbamate, acamprosate, and MRZ 2/579. The invention provides oral, controlled or sustained release, i.v., rectal, transcutaneous, or other prepns., e.g. lipid emulsion or crystal technol.
AN 2004:433774 HCAPLUS <<LOGINID::20070820>>
DN 140:400102
TI Compositions and methods using NMDA antagonists for treating neurological disease and providing neuroprotection
IN Kozachuk, Walter E.
PA USA
SO U.S. Pat. Appl. Publ., 34 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004102525	A1	20040527	US 2003-442985	20030522 <--

PRAI US 2002-382072P P 20020522 <--
IT 209185-99-9, MRZ 2/579
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NMDA antagonists for treating neurol. disease and providing neuroprotection)
RN 209185-99-9 HCAPLUS
CN Cyclohexanamine, 1,3,3,5,5-pentamethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of protein Tau
AB Aminocyclohexane and aminoalkylcyclohexane compds., which are systemically-active as NMDA receptor antagonists, are effective in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau, method of treating disorders resulting from or associated with abnormal hyperphosphorylation of microtubule associated protein tau, and pharmaceutical compns. comprising the same.
AN 2004:80486 HCAPLUS <<LOGINID::20070820>>
DN 140:139523
TI NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of protein Tau
IN Iqbal, Khalid; Grundke-Iqbal, Inge
PA USA
SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004009062	A2	20040129	WO 2003-US22362	20030717 <--
	WO 2004009062	A3	20041223		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004019118	A1	20040129	US 2003-622163	20030717 <--
	AU 2003251993	A1	20040209	AU 2003-251993	20030717 <--
	EP 1523309	A2	20050420	EP 2003-765660	20030717 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	ZA 2005001430	A	20060726	ZA 2005-1430	20050217 <--
PRAI	US 2002-397434P	P	20020719 <--		
	WO 2003-US22362	W	20030717		

OS MARPAT 140:139523
IT 219810-59-0, Neramexane 219810-60-3 219810-61-4
219810-62-5 219810-65-8 219810-66-9
219810-67-0 219810-68-1 219810-69-2
259734-12-8 259734-13-9 259734-14-0
259734-15-1 259734-16-2 259747-71-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(NMDA receptor antagonists and inhibition of abnormal hyperphosphorylation of tau)

RN 219810-59-0 HCAPLUS
CN Cyclohexanamine, 1,3,3,5,5-pentamethyl- (CA INDEX NAME)



RN 219810-60-3 HCAPLUS
CN Cyclohexanamine, 3-ethyl-1,3,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 219810-61-4 HCAPLUS
CN Cyclohexanamine, 3,3-diethyl-1,5,5-trimethyl- (9CI) (CA INDEX NAME)



RN 219810-62-5 HCAPLUS
CN Cyclohexanamine, 5-ethyl-1,3,3-trimethyl-, (1R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 219810-65-8 HCAPLUS
CN Cyclohexanamine, 5-ethyl-1,3,3-trimethyl-, (1R,5S)-rel- (9CI) (CA INDEX

NAME)

Relative stereochemistry.



RN 219810-66-9 HCAPLUS
CN Cyclohexanamine, 1-ethyl-3,3,5,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 219810-67-0 HCAPLUS
CN Cyclohexanamine, 3,3,5,5-tetramethyl-1-propyl- (9CI) (CA INDEX NAME)



RN 219810-68-1 HCAPLUS
CN Cyclohexanamine, N,1,3,3,5,5-hexamethyl- (9CI) (CA INDEX NAME)



RN 219810-69-2 HCAPLUS
CN Cyclohexanamine, N-ethyl-1,3,3,5,5-pentamethyl- (9CI) (CA INDEX NAME)



RN 259734-12-8 HCAPLUS
CN Cyclohexanamine, 1,3,5-trimethyl- (9CI) (CA INDEX NAME)



RN 259734-13-9 HCAPLUS
CN Cyclohexanamine, 1,3,5-trimethyl-, (1α,3β,5β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 259734-14-0 HCAPLUS
CN Cyclohexanamine, 1,3,3,5-tetramethyl- (9CI) (CA INDEX NAME)



RN 259734-15-1 HCAPLUS
CN Cyclohexanamine, 5-ethyl-1,3,3-trimethyl-, (1S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259734-16-2 HCAPLUS
CN Cyclohexanamine, 5-ethyl-1,3,3-trimethyl-, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259747-71-2 HCAPLUS
CN Cyclohexanamine, 1,3,5-trimethyl-, (1α,3α,5α)- (9CI)
(CA INDEX NAME)

Relative stereochemistry.



L10 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Tetracycline compounds having target therapeutic activities
AB Methods and compds. for treating a variety of diseases with tetracycline compds. having a target therapeutic activity are described, as is compound preparation
AN 2003:57866 HCAPLUS <<LOGINID::20070820>>
DN 138:117673
TI Tetracycline compounds having target therapeutic activities
IN Levy, Stuart B.; Draper, Michael; Nelson, Mark L.; Jones, Graham
PA Paratek Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003005971	A2	20030123	WO 2002-US22451	20020715 <--
	WO 2003005971	A3	20031127		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002318238 A1 20030129 AU 2002-318238 20020715 <--
US 2004063674 A1 20040401 US 2002-196010 20020715 <--
EP 1408987 A2 20040421 EP 2002-748169 20020715 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
JP 2004537544 T 20041216 JP 2003-511780 20020715 <--
US 2006194773 A1 20060831 US 2004-996119 20041122 <--
PRAI US 2001-305546P P 20010713 <--
US 2002-395741P P 20020712 <--
US 2002-196010 A2 20020715 <--
WO 2002-US22451 W 20020715 <--
US 2003-441141P P 20030116
US 2004-759484 B1 20040116
OS MARPAT 138:117673
IT 389139-91-7 460068-44-4 460071-09-4
460073-92-1 460074-11-7 488817-96-5
488819-45-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(tetracycline compds. with target therapeutic activities)
RN 389139-91-7 HCAPLUS
CN 2-Naphthacenecarboxamide, 9-[(cyclohexylmethyl)amino]-4,7-
bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-
1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 460068-44-4 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-N-(1-ethylcyclohexyl)-
1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-
dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 460071-09-4 HCAPLUS
CN 2-Naphthacenecarboxamide, 7-[5-[(cyclohexylamino)methyl]-2-methoxyphenyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 460073-92-1 HCAPLUS
CN 2-Naphthacenecarboxamide, 7-[5-[(cyclohexylamino)methyl]-2-furanyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 460074-11-7 HCAPLUS
CN 2-Naphthacenecarboxamide, 9-[[(cyclohexylmethyl)amino]methyl]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 488817-96-5 HCAPLUS
CN 2-Naphthacenecarboxamide, 9-[[(cyclohexylamino)iminomethyl]amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 488819-45-0 HCAPLUS
CN 2-Naphthacenecarboxamide, 9-[(cyclohexylamino)methyl]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of carboxamides as NMDA receptor antagonists
GI



I

AB The title compds. [I; R1-R4 = H, halo, OH, etc,; two of neighboring R1-R4 groups together with one or more identical or different addnl. heteroatom and CH and/or CH2 groups can form 4-7 membered homo- or heterocyclic ring; one of R5 and R6 = H and the other = phenylcyclohexyl, alkyl; or NR5R6 = (un)substituted (un)saturated 4-6 membered heterocyclic ring; X, Y = O, N, S, CH, etc.] were prepared and formulated. Thus, reacting 5-hydroxyindole-2-carboxylic acid with 4-benzylpiperidine in the presence of Et3N and HBTU in MeCN afforded 31% I [X = NH; Y = CH; R1, R3, R4 = H; R2 = OH; NR5R6 = 4-benzylpiperidin-1-yl] which showed IC50 of 0.024 μM in NMDA receptor assay. The compds. I are highly effective and selective antagonists of NMDA receptor, and moreover most of the compds. I are selective antagonist of NR2B subtype of NMDA receptor.
AN 2002:332162 HCAPLUS <<LOGINID::20070820>>
DN 136:355158
TI Preparation of carboxamides as NMDA receptor antagonists
IN Horvath, Csilla; Farkas, Sandor; Domany, Gyoergy; Borza, Istvan; Bartane Szalai, Gizella; Nagy, Jozsef; Kolok, Sandor
PA Richter Gedeon Vegyeszeti Gyar Rt., Hung.
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002034718	A1	20020502	WO 2001-HU99	20011015 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

HU 200004123	A2	20021028	HU 2000-4123	20001024	<--
HU 200004123	A3	20030328			
AU 200210782	A	20020506	AU 2002-10782	20011015	<--
EP 1328514	A1	20030723	EP 2001-978687	20011015	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004512324	T	20040422	JP 2002-537711	20011015	<--
RU 2271361	C2	20060310	RU 2003-115490	20011015	<--
US 2003199552	A1	20031023	US 2003-412977	20030411	<--
US 6919355	B2	20050719			
US 2005113359	A1	20050526	US 2004-24637	20041228	<--
US 2005113360	A1	20050526	US 2004-24638	20041228	<--
US 2005113361	A1	20050526	US 2004-25288	20041229	<--
US 2005159451	A1	20050721	US 2004-25287	20041229	<--
PRAI HU 2000-4123	A	20001024	<--		
WO 2001-HU99	W	20011015	<--		
US 2003-412977	A3	20030411			

OS MARPAT 136:355158

IT 420136-37-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carboxamides as NMDA receptor antagonists)

RN 420136-37-4 HCAPLUS

CN 1H-Indole-2-carboxamide, 6-hydroxy-N-(4-phenylcyclohexyl)- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN

TI The N-methyl-d-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonize 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner

AB The type 3 serotonin (5-HT3) receptor is a ligand-gated ion channel. In concentration-clamp expts., we investigated the effects of the uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonists memantine, amantadine and MRZ 2/579 on 5-HT receptors stably expressed in HEK-293 cells and on native 5-HT3 receptors in the N1E-115 cell line. All agents antagonized serotonin (10 μM)-induced inward currents with similar potency to that reported for NMDA receptors. This effect was characterized by inducing a pronounced receptor desensitization, and was probably non-competitive and voltage-independent. In contrast, (S)-ketamine was much weaker as an antagonist of 5-HT3 receptors than NMDA

receptors. Similar effects on 5-HT3 receptors have been reported previously for a variety of anti-depressants and it is possible that the clin. anti-depressant effects reported for both memantine and amantadine are mediated, at least in part, by antagonistic effects at 5-HT3 receptors.

AN 2001:429280 HCAPLUS <<LOGINID::20070820>>
DN 135:251854
TI The N-methyl-d-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonize 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner
AU Rammes, G.; Rupprecht, R.; Ferrari, U.; Zieglgansberger, W.; Parsons, C. G.
CS Max-Planck-Institute of Psychiatry, Munchen, D-80804, Germany
SO Neuroscience Letters (2001), 306(1-2), 81-84
CODEN: NELED5; ISSN: 0304-3940
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
IT 209185-99-9, MRZ 2/579 219835-40-2, MRZ 2/621
219835-43-5, MRZ 2/616 219835-44-6, MRZ 2/607
219835-50-4, MRZ 2/633 219835-51-5, MRZ 2/632
219835-55-9, MRZ 2/601 219835-56-0, MRZ 2/615
219835-60-6, MRZ 2/640 219835-62-8, MRZ 2/642
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonize 5-HT3 receptor currents in HEK-293 and N1E-115 cells)
RN 209185-99-9 HCAPLUS
CN Cyclohexanamine, 1,3,3,5,5-pentamethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 219835-40-2 HCAPLUS
CN Cyclohexanamine, 1,3,3-trimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 219835-43-5 HCAPLUS
CN Cyclohexanamine, 1,3,5-trimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 219835-44-6 HCAPLUS
CN Cyclohexanamine, 1,3,3,5-tetramethyl-, hydrochloride, (1R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 219835-50-4 HCAPLUS
CN Cyclohexanamine, 5-ethyl-1,3,3-trimethyl-, hydrochloride, (1R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 219835-51-5 HCAPLUS
CN Cyclohexanamine, 5-ethyl-1,3,3-trimethyl-, hydrochloride, (1R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 219835-55-9 HCAPLUS
CN Cyclohexanamine, 3,3,5,5-tetramethyl-1-propyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 219835-56-0 HCAPLUS
CN Cyclohexanamine, 3-ethyl-1,3,5,5-tetramethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 219835-60-6 HCAPLUS
CN Cyclohexanamine, N,1,3,3,5,5-hexamethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 219835-62-8 HCAPLUS
CN Cyclohexanamine, N,N,1,3,3,5,5-heptamethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The compds. [I, II, III; R1 and R3 are independently selected from (un)substituted Ph, benzyl, phenoxy, H, alkyl, OH, etc.; R2 and R5 are independently selected from H, alkyl, hydroxyalkyl; R2-R5 together are imino; R1-R2 together are (CH2)n, (CH2)n-N(R6)-(CH2)n; n = 0-6, at least one n greater than 0; R6 is H, alkyl, 2-hydroxyethyl, and alkylphenyl; R4 is selected from (un)substituted thiofuryl, pyridyl, Ph, benzyl, phenoxy, phenylthio, H, alkyl, chcloalkyl; X, X1 is independently selected from (un)substituted Ph, benzyl, phenoxy, F, Cl, Br, Oh, etc.; m = 0-5; Y is N(R6)2, H when R1-R2 together are (CH2)n-N(R6)-(CH2)n], pharmaceutical compns., and pharmaceutical acceptable salts, complexes, and carriers are prepared as antagonists of NMDA receptor-mediated responses for treating a neurol. disease or disorder such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral

sclerosis (ALS).
AN 1999:7958 HCAPLUS <<LOGINID::20070820>>
DN 130:66268
TI Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
IN Mueller, Alan L.; Moe, Scott T.
PA NPS Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 252 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9856752	A1	19981217	WO 1998-US11608	19980611	<--
	W: JP					
	AU 770292	B2	20040219	AU 2000-71810	20001124	<--
	AU 2004202114	A1	20040610	AU 2004-202114	20040518	<--
PRAI	US 1997-873011	A	19970611	<--		
	AU 1997-13525	A3	19961211	<--		
	AU 2000-71810	A3	20001124	<--		

OS MARPAT 130:66268
IT 186496-25-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compds. active at novel site on receptor-operated calcium channels useful for treatment of neurol. disorders and diseases)
RN 186496-25-3 HCAPLUS
CN Cyclohexanamine, 4-(diphenylmethyl)- (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 16:09:21 ON 20 AUG 2007)

FILE 'REGISTRY' ENTERED AT 16:09:37 ON 20 AUG 2007
L1 STRUCTURE UPLOADED
L2 50 S L1
L3 STRUCTURE UPLOADED
L4 50 S L3
L5 220203 S L3 SSS FULL

FILE 'STNGUIDE' ENTERED AT 16:11:38 ON 20 AUG 2007

FILE 'HCAPLUS' ENTERED AT 16:13:22 ON 20 AUG 2007
L6 8189 S L5/THU
L7 68084 S ALZHEIMER OR DONEPEZIL OR ACETYLCHOLINESTERASE

FILE 'STNGUIDE' ENTERED AT 16:14:07 ON 20 AUG 2007

FILE 'HCAPLUS' ENTERED AT 16:14:48 ON 20 AUG 2007

```
L8         20980 S (NMDA OR (N-METHYL-D-ASPARTATE))(W)(INHIB? OR ANTAGON? OR REC
L9            38 S L6 AND L7 AND L8
L10           13 S L9 AND (PY<2003 OR AY<2003 OR PRY<2003)

     FILE 'STNGUIDE' ENTERED AT 16:14:55 ON 20 AUG 2007

     FILE 'HCAPLUS' ENTERED AT 16:15:06 ON 20 AUG 2007

     FILE 'STNGUIDE' ENTERED AT 16:15:06 ON 20 AUG 2007

     FILE 'HCAPLUS' ENTERED AT 16:16:00 ON 20 AUG 2007

     FILE 'STNGUIDE' ENTERED AT 16:16:07 ON 20 AUG 2007

=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.06     235.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -7.02

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:16:24 ON 20 AUG 2007

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'STNGUIDE' AT 16:30:49 ON 20 AUG 2007
FILE 'STNGUIDE' ENTERED AT 16:30:49 ON 20 AUG 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.06     235.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -7.02

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.30     236.18

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -7.02

FILE 'HCAPLUS' ENTERED AT 16:33:07 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 20 Aug 2007 VOL 147 ISS 9
FILE LAST UPDATED: 19 Aug 2007 (20070819/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s neramexane or memantine

	42	NERAMEXANE
	1059	MEMANTINE
L11	1072	NERAMEXANE OR MEMANTINE

=> s donepezil or acetylcholinesterase

	1130	DONEPEZIL
	23372	ACETYLCHOLINESTERASE
L12	24047	DONEPEZIL OR ACETYLCHOLINESTERASE

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.60	238.78

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.02

FILE 'STNGUIDE' ENTERED AT 16:33:09 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 17, 2007 (20070817/UP).

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	238.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.02

FILE 'HCAPLUS' ENTERED AT 16:33:55 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Aug 2007 VOL 147 ISS 9
FILE LAST UPDATED: 19 Aug 2007 (20070819/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s (l8 or L11) and l12

L13 279 (L8 OR L11) AND L12

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.60	241.44

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.02

FILE 'STNGUIDE' ENTERED AT 16:33:57 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 17, 2007 (20070817/UP).

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	241.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.02

FILE 'HCAPLUS' ENTERED AT 16:34:27 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Aug 2007 VOL 147 ISS 9
FILE LAST UPDATED: 19 Aug 2007 (20070819/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l13 and (PY<2003 or AY<2003 or PRY<2003)

```
      22880660 PY<2003
       4450548 AY<2003
       3929122 PRY<2003
L14          90 L13 AND (PY<2003 OR AY<2003 OR PRY<2003)
```

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.60	244.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.02

FILE 'STNGUIDE' ENTERED AT 16:34:31 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 17, 2007 (20070817/UP).

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	244.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.02

FILE 'HCAPLUS' ENTERED AT 16:34:50 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 20 Aug 2007 VOL 147 ISS 9
FILE LAST UPDATED: 19 Aug 2007 (20070819/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l11 and l14

L15 31 L11 AND L14

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.60	246.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.02

FILE 'STNGUIDE' ENTERED AT 16:34:52 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 17, 2007 (20070817/UP).

=> d l15 1-31 ti
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L15 ANSWER 1 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Therapeutic formulations for the treatment of β-amyloid-related diseases

L15 ANSWER 2 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Thin-film drug delivery device

L15 ANSWER 3 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Dual controlled release osmotic device comprising two different active agents

L15 ANSWER 4 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Composition and method for potentiating drugs using chemoreceptor stimulants

L15 ANSWER 5 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Therapeutic formulations for the treatment of beta-amyloid related diseases containing two active ingredients

L15 ANSWER 6 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Compositions and methods using NMDA antagonists for treating neurological disease and providing neuroprotection

L15 ANSWER 7 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Drug condensation aerosols and kits

L15 ANSWER 8 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Stereoisomers of p-hydroxy-milnacipran, and therapeutic use

L15 ANSWER 9 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors for treatment of dementia

L15 ANSWER 10 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation and combination therapy of cyclohexanamines and acetylcholinesterase inhibitors for treatment of dementia

L15 ANSWER 11 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Methods and compositions using cholinesterase inhibitors for the treatment

of nervous system disorders and other conditions

L15 ANSWER 12 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Endothelin antagonists for treating Alzheimer's disease and dementias of vascular origin

L15 ANSWER 13 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI A combination of an NMDA-antagonist and acetylcholinesterase inhibitors for the treatment of Alzheimer's disease

L15 ANSWER 14 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Pharmaceutical composition and method using a GABA analog, an NMDA antagonist, and an optional additional drug for treating disorders of the central nervous system

L15 ANSWER 15 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Buccal sprays or capsules containing drugs for treating disorders of the central nervous system

L15 ANSWER 16 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Involvement of nitric oxide in myotoxicity produced by diisopropylphosphorofluoridate (DFP)-induced muscle hyperactivity

L15 ANSWER 17 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Memantine treatment improves antidotal efficacy of atropine, HI-6 and diazepam in rats poisoned with soman

L15 ANSWER 18 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Efficacy of oximes and adamantanes against soman poisoning in mice

L15 ANSWER 19 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Treatment with donepezil in Alzheimer patients with and without cerebrovascular disease

L15 ANSWER 20 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Perspectives in the treatment of vascular dementia

L15 ANSWER 21 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Evaluation of memantine for neuroprotection in dementia

L15 ANSWER 22 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Role of high-energy phosphates and their metabolites in protection of carbofuran-induced biochemical changes in diaphragm muscle by Memantine

L15 ANSWER 23 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use

L15 ANSWER 24 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Assessment of primary neuronal culture as a model for soman-induced neurotoxicity and effectiveness of memantine as a neuroprotective drug

L15 ANSWER 25 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Protection and reversal by memantine and atropine of carbofuran-induced changes in biomarkers

L15 ANSWER 26 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Potential of memantine, D-tubocurarine, and atropine in preventing acute toxic myopathy induced by organophosphate nerve agents: soman, sarin, tabun and VX

L15 ANSWER 27 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Subacute toxicity of aldicarb: prevention and treatment with memantine and atropine

L15 ANSWER 28 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Novel effects of memantine in antagonizing acute aldicarb toxicity: mechanistic and applied considerations

L15 ANSWER 29 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Prophylactic and therapeutic efficacy of memantine against seizures produced by soman in the rat

L15 ANSWER 30 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Methyl parathion acute toxicity: prophylaxis and therapy with memantine and atropine

L15 ANSWER 31 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Prevention and antagonism of acute carbofuran intoxication by memantine and atropine

=> d l15 5 6 9 10 11 13 14 19 21 23 25 26 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L15 ANSWER 5 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Therapeutic formulations for the treatment of beta-amyloid related diseases containing two active ingredients
AB This invention relates to methods and pharmaceutical compns. for treating amyloid-β related diseases, including Alzheimer's disease. The invention, for example, includes a method of concomitant therapeutic treatment of a subject, comprising administering an effective amount of a first agent and a second agent, wherein said first agent treats an amyloid-β disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement. Pharmaceutical compns. containing compds. of the invention and a kit containing pharmaceutical formulations of the invention are also claimed.
AN 2004:565091 HCAPLUS <<LOGINID::20070820>>
DN 141:99726
TI Therapeutic formulations for the treatment of beta-amyloid related diseases containing two active ingredients
IN Gervais, Francine; Bellini, Francesco
PA Neurochem International Limited, Switz.
SO PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058258	A1	20040715	WO 2003-CA2011	20031224 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2511606	A1	20040715	CA 2003-2511606	20031224 <--
	AU 2003291910	A1	20040722	AU 2003-291910	20031224 <--

```
     EP 1585520           A1    20051019    EP 2003-767368          20031224 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003017747        A     20051122    BR 2003-17747           20031224 <--
     CN 1753662           A     20060329    CN 2003-80109946        20031224 <--
     CN 1753675           A     20060329    CN 2003-80109952        20031224 <--
     JP 2006512417        T     20060413    JP 2005-509679          20031224 <--
     US 2005031651        A1    20050210    US 2004-871537          20040618 <--
     NO 2005003077        A     20050922    NO 2005-3077            20050623 <--
     MX 2005PA06940       A     20060222    MX 2005-PA6940          20050624 <--
     IN 2005CN01675       A     20070622    IN 2005-CN1675          20050722 <--
PRAI US 2002-436379P      P     20021224  <--
     US 2003-482214P      P     20030623
     US 2003-480906P      P     20030623
     US 2003-480918P      P     20030623
     US 2003-480984P      P     20030623
     US 2003-482058P      P     20030623
     US 2003-512017P      P     20031017
     US 2003-512047P      P     20031017
     US 2003-512116P      P     20031017
     US 2003-512135P      P     20031017
     US 2003-746138       A2    20031224
     WO 2003-CA2011       W     20031224
OS   MARPAT 141:99726

L15  ANSWER 6 OF 31  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Compositions and methods using NMDA antagonists for
     treating neurological disease and providing neuroprotection
AB   The invention provides pharmaceutical compns. and methods of use thereof
     for the acute, chronic, and prophylactic treatment of neurol. and
     neurodegenerative diseases, attenuation of acute or chronic neuronal
     damage in neurol. disease (neuroprotection), and prophylaxis of neurol.
     diseases, where the neurol. diseases may involve excessive stimulation of
     the NMDA receptor, hypofunction of the NMDA
     receptor, up- or down regulation of the NMDA
     receptor, and abnormal subunit structure or function of the
     NMDA receptor.  The pharmaceutical compns. are
     open-channel antagonists of the NMDA receptor complex,
     and include memantine, felbamate, acamprosate, and MRZ 2/579.
     The invention provides oral, controlled or sustained release, i.v.,
     rectal, transcutaneous, or other prepns., e.g. lipid emulsion or crystal
     technol.
AN   2004:433774  HCAPLUS <<LOGINID::20070820>>
DN   140:400102
TI   Compositions and methods using NMDA antagonists for
     treating neurological disease and providing neuroprotection
IN   Kozachuk, Walter E.
PA   USA
SO   U.S. Pat. Appl. Publ., 34 pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   US 2004102525         A1    20040527    US 2003-442985          20030522 <--
PRAI US 2002-382072P       P     20020522  <--

L15  ANSWER 9 OF 31  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Combination therapy using 1-aminocyclohexane derivatives and
     acetylcholinesterase inhibitors for treatment of dementia
AB   The invention relates to a novel drug combination therapy useful in the
     treatment of dementia comprising administering an 1-aminocyclohexane
     derivative such as memantine or neramexane and an
```

acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine. Patients with Alzheimer's disease were treated with memantine in combination with donepezil for about 4 mo. Global clin. status of most patients improved (54%) or remained stable (39%).

AN 2004:372886 HCAPLUS <<LOGINID::20070820>>
DN 140:368722
TI Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors for treatment of dementia
IN Moebius, Hans-Joerg
PA Germany
SO U.S. Pat. Appl. Publ., 46 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004087658	A1	20040506	US 2003-691895	20031023 <--
CN 1720035	A	20060111	CN 2003-80104613	20031023 <--
ZA 2005003204	A	20060726	ZA 2005-3204	20050420 <--
PRAI US 2002-420918P	P	20021024 <--		

OS MARPAT 140:368722

L15 ANSWER 10 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation and combination therapy of cyclohexanamines and acetylcholinesterase inhibitors for treatment of dementia
GI



I



II

AB The invention relates to a drug combination therapy useful in the treatment of dementia associated with disorders of the central nervous system, e.g. to delay the onset or progression of Alzheimer's disease, cerebrovascular disease, or Down's syndrome, comprising a combination of a 1-aminocyclohexane derivative I [wherein R = An(CR1R2)mNR3R4; n + m = 0-2; A = alkylene, alkenylene, or alkynylene; R1 and R2 = independently H, alkyl, alkenyl, alkynyl, or (un)substituted aryl(alkyl); R3 and R4 = independently H, alkyl, alkenyl, alkynyl, etc.; or NR3R4 = azacycloalkyl or azacycloalkenyl; R5 = independently H, alkyl, alkenyl, or alkynyl; or R5 may combine with the C to which it is attached and an adjacent ring carbon to form a double bond; R6-R9 = independently H, (cyclo)alkyl, alkenyl, alkynyl, or (un)substituted aryl(alkyl); or R6-R9 may combine to form an alkylene or alkenylene bridge; and optical isomers, diastereomers, polymorphs, enantiomers, hydrates, pharmaceutically acceptable salts thereof], such as memantine or neramexane, and an acetylcholinesterase inhibitor (AChEI), such as galantamine, tacrine, donepezil, or rivastigmine. Examples include synthesis of cyclohexanamines and azabicycles and clin. trials of combination therapy of a cyclohexanamine with an AChEI. For instance, coupling of tri-Et phosphonoacetate and 3,3,5,5-tetramethylcyclohexanone in the presence of NaH in THF gave Et 2-(3,3,5,5-tetramethylcyclohexylidene)aceta te (86%), which was reduced to the alc. (89%) using LiAlH4 in dry ether. Reductive addition of trichloroacetonitrile to the enol using NaH in di-Et

ether (66%), followed by N-deprotection with NaOH in DMSO provided II•HCl (53%). Combination therapy comprising memantine and donepezil was evaluated in a double blind study of 403 Alzheimer's disease patients. Patients treated with memantine and donepezil showed clin. and statistically significant improvement ($p<0.001$) in cognitive function (Severe Impairment Battery Test) as compared to patients treated with donepezil and placebo, and showed significantly less decline ($p=0.028$) in daily function (AD Cooperative Study - Activities of Daily Living Inventory). The combination was safe and well tolerated, resulting in a similar incidence of treatment-emergent adverse events as donepezil/placebo.

AN 2004:368913 HCAPLUS <<LOGINID::20070820>>
DN 140:395498
TI Preparation and combination therapy of cyclohexanamines and acetylcholinesterase inhibitors for treatment of dementia
IN Moebius, Hans-Joerg
PA Merz Pharma G.m.b.H. & Co. K.-G.a.A., Germany; Marsden, John Christopher
SO PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004037234	A2	20040506	WO 2003-GB4549	20031023 <--
	WO 2004037234	A3	20040805		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2502432	A1	20040506	CA 2003-2502432	20031023 <--
	AU 2003274353	A1	20040513	AU 2003-274353	20031023 <--
	AU 2003274353	B2	20070405		
	EP 1556019	A2	20050727	EP 2003-758338	20031023 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1720035	A	20060111	CN 2003-80104613	20031023 <--
	JP 2006506378	T	20060223	JP 2004-546158	20031023 <--
	MX 2004PA06900	A	20041015	MX 2004-PA6900	20040715 <--
	ZA 2005003204	A	20060726	ZA 2005-3204	20050420 <--
	NO 2005002462	A	20050720	NO 2005-2462	20050523 <--
PRAI	US 2002-420918P	P	20021024 <--		
	WO 2003-GB4549	W	20031023		

OS MARPAT 140:395498

L15 ANSWER 11 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Methods and compositions using cholinesterase inhibitors for the treatment of nervous system disorders and other conditions
AB The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alc. syndrome, Korsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic stress disorder, anxiety disorders, panic attacks, obsessive-compulsive disorder, amnesia, and other disorders by administering to a patient in need thereof at least one cholinesterase inhibitor. The invention also provides novel

pharmaceutical compns. that can be administered to the eyes or to the nose of patients. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof. In other embodiments, the cholinesterase inhibitor can be one or more of phenserine, tolserine, phenethylnorcymserine, ganstigmine, epastigmine, tacrine, physostigmine, pyridostigmine, neostigmine, rivastigmine, galantamine, citicoline, velnacrine, huperzine, metrifonate, heptastigmine, edrophonium, TAK-147, T-82, and upreazine.

AN 2004:354723 HCAPLUS <<LOGINID::20070820>>
DN 140:368732
TI Methods and compositions using cholinesterase inhibitors for the treatment of nervous system disorders and other conditions
IN Ieni, John; Pratt, Raymond
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004034963	A2	20040429	WO 2003-US15279	20030516 <--
	WO 2004034963	A3	20040722		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003298514	A1	20040504	AU 2003-298514	20030516 <--
	US 2006018839	A1	20060126	US 2004-988600	20041116 <--
	US 2007053976	A1	20070308	US 2006-523803	20060920 <--
PRAI	US 2002-380852P	P	20020517	<--	
	US 2003-447724P	P	20030219		
	WO 2003-US15279	W	20030516		
	US 2004-988600	A2	20041116		
	JP 2005-276222	A	20050922		

OS MARPAT 140:368732

L15 ANSWER 13 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI A combination of an NMDA-antagonist and acetylcholinesterase inhibitors for the treatment of Alzheimer's disease
AB A pharmaceutical composition comprising (a) an effective amount of one or more of acetylcholinesterase inhibitor(s) or a pharmaceutically effective salt thereof and (b) an effective amount of one or more NMDA-antagonist(s) is disclosed for treatment of Alzheimer's disease.
AN 2003:971893 HCAPLUS <<LOGINID::20070820>>
DN 140:8859
TI A combination of an NMDA-antagonist and acetylcholinesterase inhibitors for the treatment of Alzheimer's disease
IN Thomsen, Lars Lykke; Pedersen, Anders Gersel
PA H. Lundbeck A/s, Den.
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003101458	A1	20031211	WO 2003-DK342	20030522 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2426492	A1	20030916	CA 2003-2426492	20030508 <--
	CA 2426492	C	20061003		
	CA 2558708	A1	20030916	CA 2003-2558708	20030508 <--
	AU 2003227516	A1	20031219	AU 2003-227516	20030522 <--
	EP 1509232	A1	20050302	EP 2003-724895	20030522 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003011375	A	20050315	BR 2003-11375	20030522 <--
	CN 1655793	A	20050817	CN 2003-812161	20030522 <--
	JP 2005528431	T	20050922	JP 2004-508815	20030522 <--
	NZ 536603	A	20070629	NZ 2003-536603	20030522 <--
	ZA 2004009147	A	20060628	ZA 2004-9147	20041111 <--
	MX 2004PA11762	A	20050331	MX 2004-PA11762	20041126 <--
	NO 2004005434	A	20041213	NO 2004-5434	20041213 <--
	IN 2004CN02954	A	20060217	IN 2004-CN2954	20041228 <--
PRAI	DK 2002-844	A	20020531	<--	
	US 2002-384467P	P	20020531	<--	
	CA 2003-2426492	A3	20030508		
	WO 2003-DK342	W	20030522		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 14 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Pharmaceutical composition and method using a GABA analog, an NMDA antagonist, and an optional additional drug for treating disorders of the central nervous system

AB Disorders of the central nervous system (CNS) are treated by the administration of a GABA analog (e.g. gabapentin or pregabalin), an NMDA receptor antagonist (e.g. dextromethorphan or d-methadone), and, optionally, another pharmacol. active substance, e.g., one which is effective for the treatment of a CNS disorder.

AN 2003:591003 HCAPLUS <<LOGINID::20070820>>

DN 139:128044

TI Pharmaceutical composition and method using a GABA analog, an NMDA antagonist, and an optional additional drug for treating disorders of the central nervous system

IN Galer, Bradley S.; Schlagheck, Thomas G.

PA Endo Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003061656	A1	20030731	WO 2003-US794	20030110 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				

PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2473536	A1	20030731	CA 2003-2473536	20030110	<--
EP 1471909	A1	20041103	EP 2003-731905	20030110	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005518411	T	20050623	JP 2003-561600	20030110	<--
CN 1642547	A	20050720	CN 2003-806180	20030110	<--
AU 2003210486	B2	20070628	AU 2003-210486	20030110	<--
US 2006167032	A1	20060727	US 2005-501678	20050712	<--
PRAI US 2002-349773P	P	20020116	<--		
WO 2003-US794	W	20030110			

OS MARPAT 139:128044
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 19 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Treatment with donepezil in Alzheimer patients with and without cerebrovascular disease
AB Donepezil, a selective acetylcholinesterase inhibitor, is approved for the symptomatic treatment of mild to moderate Alzheimer's disease (AD). In a post-marketing surveillance (PMS) study in Germany, patients under routine treatment conditions were observed while treatment was switched from other antidementia drugs (i.e., nootropics) to donepezil. A total of 913 patients were enrolled (60.1% female, mean age 73.4 yr, mean Mini-Mental Status Examination [MMSE] 18.0), and were treated with donepezil (5 or 10 mg/day according to recommended dosing). Seven-hundred nine of 913 (77.1%) patients had been pretreated with other antidementive drugs (piracetam, memantine, ginkgo, and others). In 29.6% of patients, investigators documented concomitant cerebrovascular disease (CVD+) according to their clin. judgment. Observation period was 3 mo for the individual patient. Efficacy parameters were changes in MMSE, global clin. (investigators) judgment of efficacy, and a clin. judgment about the patients' quality of life (QoL). Adverse events were also analyzed. The objective of the present investigation was to compare-in a "real-life" setting-the differential efficacy and tolerability of donepezil in AD patients with and without concomitant cerebrovascular disease. After 3 mo, patients had improved by a mean MMSE change from baseline of 2.2 points (CVD+: 2.4 pts, CVD-: 2.1 pts). QoL was judged "improved" in 70.0% of patients (CVD+: 72.5%, CVD-: 69.6%). Adverse events were reported in 85/913 (9.3%) of patients (CVD+: 11.2%, CVD-: 7.9%). Reported adverse events were substantially less than reported previously in controlled clin. trials. This suggests that donepezil therapy is effective and well tolerated in AD patients, both with and without concomitant cerebrovascular disease.
AN 2002:839425 HCAPLUS <<LOGINID::20070820>>
DN 139:95222
TI Treatment with donepezil in Alzheimer patients with and without cerebrovascular disease
AU Frolich, L.; Klinger, T.; Berger, F. M.
CS Klinik fur Psychiatrie und Psychotherapie I, Klinikum der Universitat Frankfurt am Main, Frankfurt am Main, D-60528, Germany
SO Journal of the Neurological Sciences (2002), 203-204, 137-139
CODEN: JNSCAG; ISSN: 0022-510X
PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 21 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Evaluation of memantine for neuroprotection in dementia
AB A review with 35 refs. Memantine, a non-competitive NMDA antagonist, has been approved for use in the treatment of dementia in Germany for over ten years. The rationale for use is excitotoxicity as a pathomechanism of neurodegenerative disorders. Memantine acts as a neuroprotective agent against this pathomechanism, which is also implicated in vascular dementia. HIV-1 proteins Tat and gp120 have been implicated in the pathogenesis of dementia associated with HIV infection and the neurotoxicity caused by HIV-1 proteins can be blocked completely by memantine. Memantine has been investigated extensively in animal studies and following this, its efficacy and safety has been established and confirmed by clin. experience in humans. It exhibits none of the undesirable effects associated with competitive NMDA antagonists such as dizocilpine. The efficacy of memantine in a variety of dementias has been shown in clin. trials. Memantine is considered to be a promising neuroprotective drug for the treatment of dementias, particularly Alzheimer's disease for which there is no neuroprotective therapy available currently. It can be combined with acetylcholinesterase inhibitors which are the mainstay of current symptomatic treatment of Alzheimer's disease. Memantine has a therapeutic potential in numerous CNS disorders besides dementias which include stroke, CNS trauma, Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), epilepsy, drug dependence and chronic pain. If memantine is approved by the FDA for some of these indications by the year 2005, it can become a blockbuster drug by crossing the US$1 billion mark in annual sales.
AN 2000:411031 HCAPLUS <<LOGINID::20070820>>
DN 133:129433
TI Evaluation of memantine for neuroprotection in dementia
AU Jain, Kewal K.
CS Jain PharmaBiotech, Basel, CH-4057, Switz.
SO Expert Opinion on Investigational Drugs (2000), 9(6), 1397-1406
CODEN: EOIDER; ISSN: 1354-3784
PB Ashley Publications Ltd.
DT Journal; General Review
LA English
RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 23 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use
AB The loss of cholinergic neurons within the basal forebrain of patients with Alzheimer's disease (AD) may underlie aspects of the dementia. Excessive activation of N-methyl-D-aspartate (NMDA) receptors may underlie the degeneration of cholinergic cells. New drug therapies have been designed to either enhance cholinergic function by inhibition acetylcholinesterase (AChE), e.g. galanthamine, tetrahydroaminoacridine or donepezil, or by attenuation of NMDA receptor function, e.g. memantine. A combination of these two therapeutic approaches may be more beneficial at slowing the progression of the AD. The current study investigated whether memantine would attenuate the inhibition of AChE produced by these three drugs. The results indicate that these AChE inhibitors do not lose their therapeutic efficacy in combination with memantine. The authors in vitro data suggest that the clin. combination of memantine with a reversible AChE inhibitor should be a valuable pharmacotherapeutic approach to dementia.
AN 2000:146123 HCAPLUS <<LOGINID::20070820>>
DN 132:274222
TI No interaction of memantine with acetylcholinesterase

inhibitors approved for clinical use
AU Wenk, Gary L.; Quack, Guenter; Moebius, Hans-Joerg; Danysz, Wojciech
CS Arizona Research Laboratories, Division of Neural Systems, Memory & Aging, University of Arizona, Tucson, AZ, 85724, USA
SO Life Sciences (2000), 66(12), 1079-1083
CODEN: LIFSAK; ISSN: 0024-3205
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 25 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Protection and reversal by memantine and atropine of carbofuran-induced changes in biomarkers
AB Male Sprague-Dawley rats injected with a single acute dose of carbofuran (1.5 mg/kg, s.c.) developed chewing movements and fine tremors within 5-7 min. The signs of maximal severity with hypercholinergic preponderance including muscle fasciculations, convulsions, tracheobronchial secretions, and diarrhea were evident within 15-30 min and lasted for about 2 h. Toxic signs were of central, as well as peripheral, origins. Rats were free from toxic signs by 3.5 h. Various antidotal drugs, alone or in combination with atropine sulfate (ATS), were administered as pretreatment or as therapeutic measures to alleviate carbofuran-induced cholinergic toxicity. In fact, pyridine-2-aldoxime methylchloride (2-PAM) or diazepam alone or in combination with ATS did not provide any beneficial antidotal effects. Combined pretreatment with memantine (MEM, 18 mg/kg, s.c.) and ATS (16 mg/kg, s.c.) provided complete protection against carbofuran toxicity and reversal of clin. evidence when given therapeutically. Carbofuran intoxication caused significant alterations in the activities of biomarker enzymes such as creatine kinase (CK) and lactic dehydrogenase (LDH) and their isoenzymes patterns in serum as a result of their leakage from the target organs (brain, muscles, and heart). Significant increases in the levels of transaminases (GOT and GPT) and glucose were also noted. MEM in combination with ATS provided significant protection and reversal of the induced changes in the aforementioned parameters, in addition to similar protective effects reported on target enzyme acetylcholinesterase (AChE). These results, along with those reported previously, indicate that MEM antagonizes carbamates toxicity by maintaining cell membrane permeability and integrity through multiple mechanisms, in addition to the muscarinic receptor blocking effect of ATS.
AN 1993:207201 HCAPLUS <<LOGINID::20070820>>
DN 118:207201
TI Protection and reversal by memantine and atropine of carbofuran-induced changes in biomarkers
AU Gupta, Ramesh C.; Goad, John T.; Kadel, Wade L.
CS Breathitt Vet. Cent., Murray State Univ., Hopkinsville, KY, 42241-2000, USA
SO Drug Development Research (1993), 28(2), 153-60
CODEN: DDREDK; ISSN: 0272-4391
DT Journal
LA English

L15 ANSWER 26 OF 31 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Potential of memantine, D-tubocurarine, and atropine in preventing acute toxic myopathy induced by organophosphate nerve agents: soman, sarin, tabun and VX
AB Male Sprague-Dawley rats when administered s.c. a sublethal dose of organophosphorus cholinesterase inhibitors such as the nerve agents soman (100 μg/kg, s.c.), sarin (110 μg/kg, s.c.), tabun (200 μg/kg, s.c.), or VX (12 μg/kg, s.c.) developed seizures and severe muscle fasciculations within 15-20 min, lasting for 4-6 h. Marked inhibition of acetylcholinesterase (AChE) and necrotic lesions in skeletal

muscles, such as soleus, extensor digitorum longus, and diaphragm, were evident 1-24 h following injection. Pretreatment with memantine HCl (MEM, 18 mg/kg, s.c.) together with atropine sulfate (ATS, 16 mg/kg, s.c.), 60 min and 15 min, resp., prior to nerve agents attenuated AChE inhibition, prevented myonecrosis, muscle fasciculations, and other signs of cholinergic toxicity. Pretreatment combining d-tubocurarine (d-TC, 0.075 mg/kg, s.c.) and ATS (16 mg/kg, s.c.) prevented the myonecrosis and fasciculation without protecting AChE against inhibition by these nerve agents. Neither MEM, d-TC, nor ATS in the concentration given interfered with the normal behavior of the rats. The role of d-TC and ATS interaction with presynaptic receptors regulating ACh release and MEM's role in modulating neural hyperactivity as protective mechanisms are discussed.

AN 1993:34133 HCAPLUS <<LOGINID::20070820>>
DN 118:34133
TI Potential of memantine, D-tubocurarine, and atropine in preventing acute toxic myopathy induced by organophosphate nerve agents: soman, sarin, tabun and VX
AU Gupta, Ramesh C.; Dettbarn, Wolf D.
CS Breathitt Vet. Cent., Murray State Univ., Hopkinsville, KY, 42241, USA
SO Neurotoxicology (1992), 13(3), 649-61
CODEN: NRTXDN; ISSN: 0161-813X
DT Journal
LA English

=> d his

(FILE 'HOME' ENTERED AT 16:09:21 ON 20 AUG 2007)

FILE 'REGISTRY' ENTERED AT 16:09:37 ON 20 AUG 2007
L1 STRUCTURE UPLOADED
L2 50 S L1
L3 STRUCTURE UPLOADED
L4 50 S L3
L5 220203 S L3 SSS FULL

FILE 'STNGUIDE' ENTERED AT 16:11:38 ON 20 AUG 2007

FILE 'HCAPLUS' ENTERED AT 16:13:22 ON 20 AUG 2007
L6 8189 S L5/THU
L7 68084 S ALZHEIMER OR DONEPEZIL OR ACETYLCHOLINESTERASE

FILE 'STNGUIDE' ENTERED AT 16:14:07 ON 20 AUG 2007

FILE 'HCAPLUS' ENTERED AT 16:14:48 ON 20 AUG 2007
L8 20980 S (NMDA OR (N-METHYL-D-ASPARTATE))(W)(INHIB? OR ANTAGON? OR REC
L9 38 S L6 AND L7 AND L8
L10 13 S L9 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 16:14:55 ON 20 AUG 2007

FILE 'HCAPLUS' ENTERED AT 16:15:06 ON 20 AUG 2007

FILE 'STNGUIDE' ENTERED AT 16:15:06 ON 20 AUG 2007

FILE 'HCAPLUS' ENTERED AT 16:16:00 ON 20 AUG 2007

FILE 'STNGUIDE' ENTERED AT 16:16:07 ON 20 AUG 2007

FILE 'HCAPLUS' ENTERED AT 16:33:07 ON 20 AUG 2007
L11 1072 S NERAMEXANE OR MEMANTINE
L12 24047 S DONEPEZIL OR ACETYLCHOLINESTERASE

FILE 'STNGUIDE' ENTERED AT 16:33:09 ON 20 AUG 2007

```
     FILE 'HCAPLUS' ENTERED AT 16:33:55 ON 20 AUG 2007
L13          279 S (L8 OR L11) AND L12

     FILE 'STNGUIDE' ENTERED AT 16:33:57 ON 20 AUG 2007

     FILE 'HCAPLUS' ENTERED AT 16:34:27 ON 20 AUG 2007
L14           90 S L13 AND (PY<2003 OR AY<2003 OR PRY<2003)

     FILE 'STNGUIDE' ENTERED AT 16:34:31 ON 20 AUG 2007

     FILE 'HCAPLUS' ENTERED AT 16:34:50 ON 20 AUG 2007
L15           31 S L11 AND L14

     FILE 'STNGUIDE' ENTERED AT 16:34:52 ON 20 AUG 2007

     FILE 'HCAPLUS' ENTERED AT 16:34:59 ON 20 AUG 2007

     FILE 'STNGUIDE' ENTERED AT 16:35:00 ON 20 AUG 2007

     FILE 'HCAPLUS' ENTERED AT 16:36:42 ON 20 AUG 2007

     FILE 'STNGUIDE' ENTERED AT 16:36:44 ON 20 AUG 2007

=> log hold
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.06     296.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                 0.00     -16.38

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:36:53 ON 20 AUG 2007

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
  * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'STNGUIDE' AT 16:48:32 ON 20 AUG 2007
FILE 'STNGUIDE' ENTERED AT 16:48:32 ON 20 AUG 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.06     296.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                 0.00     -16.38

=> file registry
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.06     296.76
```

```
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00     -16.38

FILE 'REGISTRY' ENTERED AT 16:48:44 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 AUG 2007  HIGHEST RN 944998-48-5
DICTIONARY FILE UPDATES:  19 AUG 2007  HIGHEST RN 944998-48-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> exp neramexane/cn
E1            1     NERAMETHRIN/CN
E2            1     NERAMETHRIN EC 50/CN
E3            1 --> NERAMEXANE/CN
E4            1     NERAMEXANE MESYLATE/CN
E5            1     NERAMINE BROWN S 2R/CN
E6            1     NERAMINE ORANGE S-R/CN
E7            1     NERAMINE RED S-J/CN
E8            1     NERAMINE YELLOW S 3R/CN
E9            1     NERAMINOL/CN
E10           1     NERAN BRILLIANT BLUE F/CN
E11           1     NERAN BRILLIANT GREEN G/CN
E12           1     NERAN BRILLIANT YELLOW 2G/CN

=> s E3
L16           1 NERAMEXANE/CN

=> fiel stnguide
FIEL IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file stnguide
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    5.40     302.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00     -16.38

FILE 'STNGUIDE' ENTERED AT 16:49:08 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

```
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 17, 2007 (20070817/UP).

=> file hcaplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.06     302.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                         0.00     -16.38

FILE 'HCAPLUS' ENTERED AT 16:49:58 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 20 Aug 2007  VOL 147 ISS 9
FILE LAST UPDATED: 19 Aug 2007  (20070819/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l12 and l16

            42 L16
L17          7 L12 AND L16

=> s l17 and (PY<2003 or AY<2003 or PRY<2003)

      22880660 PY<2003
       4450548 AY<2003
       3929122 PRY<2003
L18          2 L17 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> file stnguide

COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         2.60     304.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                         0.00     -16.38

FILE 'STNGUIDE' ENTERED AT 16:50:02 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
```

LAST RELOADED: Aug 17, 2007 (20070817/UP).

=> d l18 1-2 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L18 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors for treatment of dementia
AB The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine. Patients with Alzheimer's disease were treated with memantine in combination with donepezil for about 4 mo. Global clin. status of most patients improved (54%) or remained stable (39%).
AN 2004:372886 HCAPLUS <<LOGINID::20070820>>
DN 140:368722
TI Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors for treatment of dementia
IN Moebius, Hans-Joerg
PA Germany
SO U.S. Pat. Appl. Publ., 46 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004087658	A1	20040506	US 2003-691895	20031023 <--
	CN 1720035	A	20060111	CN 2003-80104613	20031023 <--
	ZA 2005003204	A	20060726	ZA 2005-3204	20050420 <--
PRAI	US 2002-420918P	P	20021024 <--		

OS MARPAT 140:368722

L18 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation and combination therapy of cyclohexanamines and acetylcholinesterase inhibitors for treatment of dementia
GI



I



II

AB The invention relates to a drug combination therapy useful in the treatment of dementia associated with disorders of the central nervous system, e.g. to delay the onset or progression of Alzheimer's disease, cerebrovascular disease, or Down's syndrome, comprising a combination of a 1-aminocyclohexane derivative I [wherein R = An(CR1R2)mNR3R4; n + m = 0-2; A = alkylene, alkenylene, or alkynylene; R1 and R2 = independently H, alkyl, alkenyl, alkynyl, or (un)substituted aryl(alkyl); R3 and R4 = independently H, alkyl, alkenyl, alkynyl, etc.; or NR3R4 = azacycloalkyl or azacycloalkenyl; R5 = independently H, alkyl, alkenyl, or alkynyl; or R5 may combine with the C to which it is attached and an adjacent ring carbon to form a double bond; R6-R9 = independently H, (cyclo)alkyl,

alkenyl, alkynyl, or (un)substituted aryl(alkyl); or R6-R9 may combine to form an alkylene or alkenylene bridge; and optical isomers, diastereomers, polymorphs, enantiomers, hydrates, pharmaceutically acceptable salts thereof], such as memantine or neramexane, and an acetylcholinesterase inhibitor (AChEI), such as galantamine, tacrine, donepezil, or rivastigmine. Examples include synthesis of cyclohexanamines and azabicycles and clin. trials of combination therapy of a cyclohexanamine with an AChEI. For instance, coupling of tri-Et phosphonoacetate and 3,3,5,5-tetramethylcyclohexanone in the presence of NaH in THF gave Et 2-(3,3,5,5-tetramethylcyclohexylidene)aceta te (86%), which was reduced to the alc. (89%) using LiAlH4 in dry ether. Reductive addition of trichloroacetonitrile to the enol using NaH in di-Et ether (66%), followed by N-deprotection with NaOH in DMSO provided II•HCl (53%). Combination therapy comprising memantine and donepezil was evaluated in a double blind study of 403 Alzheimer's disease patients. Patients treated with memantine and donepezil showed clin. and statistically significant improvement ($p<0.001$) in cognitive function (Severe Impairment Battery Test) as compared to patients treated with donepezil and placebo, and showed significantly less decline ($p=0.028$) in daily function (AD Cooperative Study - Activities of Daily Living Inventory). The combination was safe and well tolerated, resulting in a similar incidence of treatment-emergent adverse events as donepezil/placebo.

AN 2004:368913 HCAPLUS <<LOGINID::20070820>>

DN 140:395498

TI Preparation and combination therapy of cyclohexanamines and acetylcholinesterase inhibitors for treatment of dementia

IN Moebius, Hans-Joerg

PA Merz Pharma G.m.b.H. & Co. K.-G.a.A., Germany; Marsden, John Christopher

SO PCT Int. Appl., 113 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004037234	A2	20040506	WO 2003-GB4549	20031023 <--
	WO 2004037234	A3	20040805		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2502432	A1	20040506	CA 2003-2502432	20031023 <--
	AU 2003274353	A1	20040513	AU 2003-274353	20031023 <--
	AU 2003274353	B2	20070405		
	EP 1556019	A2	20050727	EP 2003-758338	20031023 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1720035	A	20060111	CN 2003-80104613	20031023 <--
	JP 2006506378	T	20060223	JP 2004-546158	20031023 <--
	MX 2004PA06900	A	20041015	MX 2004-PA6900	20040715 <--
	ZA 2005003204	A	20060726	ZA 2005-3204	20050420 <--
	NO 2005002462	A	20050720	NO 2005-2462	20050523 <--
PRAI	US 2002-420918P	P	20021024 <--		
	WO 2003-GB4549	W	20031023		

OS MARPAT 140:395498

=> d l17 1-7 ti
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L17 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Methods and compositions for the treatment of CNS-related conditions

L17 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Methods and compositions for the treatment of CNS-related conditions

L17 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of spiro[cyclohexane-1,4'-quinazoline] derivatives for use as PDE7 inhibitors for the treatment of neuropathic pain

L17 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN
TI 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with Alzheimer's disease

L17 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic Aβ peptides in amyloidopathies

L17 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors for treatment of dementia

L17 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation and combination therapy of cyclohexanamines and acetylcholinesterase inhibitors for treatment of dementia